PD-217,014

From Wikipedia, the free encyclopedia
PD-217,014
Identifiers
  • (1α,3α,5α)-3-aminomethyl-bicyclo[3.2.0]heptane-3-acetic acid
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC10H17NO2
Molar mass183.251 g·mol−1
3D model (JSmol)
  • C1C[C@@H]2[C@H]1C[C@](C2)(CC(=O)O)CN
  • InChI=1S/C10H17NO2/c11-6-10(5-9(12)13)3-7-1-2-8(7)4-10/h7-8H,1-6,11H2,(H,12,13)/t7-,8+,10+
  • Key:NDDZVQRQVFTNSN-MBTKJCJQSA-N

PD-217,014 is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α2δ calcium channels (1 and 2). It was developed as a potentially more potent successor to gabapentin and pregabalin, along with several other analogues such as atagabalin and 4-methylpregabalin, but while PD-217,014 produces visceral analgesic effects in animal studies with higher potency and efficacy than gabapentin, it was not developed further for clinical use because of its comparatively more complex synthesis, compared to other related analogues.[1]

References[edit]

  1. ^ Ohashi K, Kawai M, Ninomiya N, Taylor C, Kurebayashi Y (2008). "Effect of a new alpha 2 delta ligand PD-217014 on visceral hypersensitivity induced by 2,4,6-trinitrobenzene sulfonic acid in rats". Pharmacology. 81 (2): 144–50. doi:10.1159/000110737. PMID 17989503. S2CID 84708161.